PUBLIC COMPANY
saveEmalex Biosciences Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
- —Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder
- phase3Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
- phase3A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
- phase1Food-effect Study of Ecopipam Pharmacokinetics
- phase1Drug Interaction Study
- phase2Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
- phase3Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
🐶 Hiring Signal
News
- Chutes & Ladders—Longtime Takeda R&D chief to depart next JuneTakeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving the company in June after twelve years in the position.fiercebiotech · 24d ago
- BioXcel files for bankruptcy, will sell assets to Teva for up to $125MTeva Pharmaceuticals is the 'stalking horse bidder' to kick off the auction process for BioXcel Therapeutics' AI-derived assets as the biotech files for Chapter 11 bankruptcy.biospace · 1mo ago
- STAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and moreAstraZeneca will resume expansion of its U.K. R&D operations after the trade deal with the U.S. included measures to lift U.K. drug spendingstat · 5mo ago
- Teva nabs experimental Tourette drug in $700M Emalex buyoutA Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.biopharma_dive · 5mo ago
comments(0)
5-min edit window · permanent after that